Skip to main content

Table 3 Changes in the CA19–9 and survival in relation to baseline platelet level in advanced pancreatic cancer patients

From: CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer

 

No. of cases

No. of events

PFS per unit decrease of CA19–9†

No. of events

OS per unit decrease of CA19–9†

Univariate HR (95% CI)

Multivariate HR* (95% CI)

Univariate HR (95% CI)

Multivariate HR* (95% CI)

Total patients

200

183

0.86 (0.78–0.95)

0.85 (0.77–0.94)

155

0.87 (0.79–0.96)

0.83 (0.74–0.93)

Baseline platelet level

 Tertile 1 (lowest)

66

59

0.69 (0.55–0.85)

0.51 (0.38–0.69)

50

0.57 (0.45–0.73)

0.45 (0.33–0.62)

 Tertile 2

67

64

0.75 (0.50–1.14)

0.85 (0.54–1.35)

52

0.72 (0.51–1.03)

0.74 (0.50–1.09)

 Tertile 3 (highest)

67

60

0.90 (0.79–1.03)

0.88 (0.75–1.02)

53

0.93 (0.80–1.08)

0.94 (0.74–1.10)

Pinteraction

  

0.026

0.034

 

0.001

< 0.001

  1. * The multivariable, stage (stage III vs. stage IV)-stratified Cox regression model initially included age (continuous), sex (female vs. male), KPS (70–80 vs. 90–100), prediagnosis body mass index (continuous), tumor location (head/uncinate vs. body/tail vs. overlapping sites), diabetes mellitus (absent vs. present), chemotherapy regimen (Gemcitabine monotherapy vs. Gemcitabine plus 5-Fu vs. Gemcitabine plus nab-PTX vs. Gemcitabine plus DDP vs. Nab-PTX plus S-1), and radiotherapy (yes vs. no). For total patients, we additionaly adjusted for platelet level (ordinal: tertile 1, 2, 3). A backward elimination with a threshold of P = 0.05 was used to select variables in the final models
  2. † CA19–9 change = ([CA19–9 at week-6]-[CA19–9 at baseline]) / (CA19–9 at baseline); per unit equals a 100% decrease
  3. Pinteraction was calculated using the Wald test for the cross-product of prediagnosis platelet level (continuous) and CA19–9 decrease (continuous) in Cox regression model
  4. Abbreviations: CI, confidence interval; HR, hazard ratio; KPS, Karnofsky Performance Status